Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

Reports FY24 revenue $6.59M, consensus $8.32M. “In 2024, we made substantial progress advancing MT-601, our lead multi antigen recognizing-T cell therapy, and laid the groundwork for continued momentum in 2025,” said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics (MRKR). “Preliminary data from our Phase 1 APOLLO study showed encouraging safety and efficacy results in lymphoma patients who relapsed after anti-CD19 CAR-T cell therapy. With a 78% objective response rate and favorable safety profile, we believe MT-601 has the potential to provide a transformative treatment option for this patient population. We look forward to sharing additional insights during a webinar in the second quarter of 2025.”